Xenon Pharmaceuticals (XENE) financial statements
Xenon Pharmaceuticals reported revenue of $8M in fiscal 2025, up 17.2% a year over 9 years.
Net income was -$346M and the operating margin -4974.3%, against -1376.4% in 2016.
Free cash flow was -$280M.
The diluted share count rose 412% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Xenon Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $311,000 | — | $7M | $32M | $18M | $9M | $0 | $0 | $8M |
| Research and development | $20M | $26M | $24M | $39M | $51M | $75M | $106M | $168M | $210M | $301M |
| Selling, general and admin | $7M | $7M | $8M | $11M | $13M | $22M | $33M | $47M | $69M | $80M |
| Operating income | -$25M | -$33M | -$38M | -$43M | -$31M | -$79M | -$129M | -$214M | -$279M | -$373M |
| Interest expense | — | — | $1M | $1M | $484,000 | — | — | — | — | — |
| Pre-tax income | — | — | -$35M | -$42M | -$29M | -$79M | -$125M | -$183M | -$238M | -$345M |
| Income tax | — | — | -$24,000 | -$23,000 | -$257,000 | -$6,000 | $118,000 | -$292,000 | -$4M | $1M |
| Net income | -$23M | -$31M | -$34M | -$42M | -$29M | -$79M | -$125M | -$182M | -$234M | -$346M |
| EPS (diluted) | -$1.48 | -$1.72 | -$1.63 | -$1.54 | -$0.81 | -$1.77 | -$2.06 | -$2.73 | -$3.01 | -$4.36 |
| Diluted shares | 15M | 18M | 19M | 26M | 35M | 44M | 61M | 67M | 78M | 79M |
| Operating margin | -1376.4% | -10474.3% | — | -627.0% | -97.3% | -428.4% | -1368.9% | — | — | -4974.3% |
| Net margin | -1275.5% | -9872.7% | — | -609.1% | -89.7% | -427.8% | -1328.9% | — | — | -4612.1% |
Balance sheet
Fiscal years, from Xenon Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $64M | $44M | $119M | $141M | $177M | $552M | $592M | $638M | $627M | $549M |
| Receivables | $200,000 | $438,000 | $151,000 | $813,000 | $2M | $3M | $986,000 | $874,000 | $1M | — |
| Total current assets | $66M | $45M | $121M | $145M | $182M | $559M | $600M | $645M | $635M | $561M |
| Property, plant and equipment | $1M | $1M | $991,000 | $2M | $4M | $4M | $6M | $10M | $10M | $9M |
| Total assets | $67M | $46M | $122M | $148M | $189M | $572M | $754M | $965M | $798M | $633M |
| Total current liabilities | $4M | $4M | $4M | $43M | $15M | $14M | $23M | $27M | $36M | $42M |
| Long-term debt | — | $6M | $15M | $11M | — | — | — | — | — | — |
| Total liabilities | $4M | $10M | $19M | $56M | $18M | $22M | $33M | $37M | $43M | $51M |
| Shareholders' equity | $64M | $36M | $103M | $92M | $171M | $550M | $721M | $928M | $755M | $582M |
| Net debt | -$17M | -$14M | -$53M | -$9M | -$45M | -$176M | -$57M | -$149M | -$143M | -$199M |
Cash flow
Fiscal years, from Xenon Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20M | -$29M | -$35M | -$5M | -$48M | -$70M | -$101M | -$151M | -$181M | -$279M |
| Capital spending | $279,000 | $315,000 | $507,000 | $1M | $3M | $2M | $3M | $6M | $3M | $799,000 |
| Free cash flow | -$20M | -$29M | -$35M | -$6M | -$51M | -$72M | -$104M | -$157M | -$184M | -$280M |
| Stock-based compensation | $2M | $2M | $3M | $3M | $6M | $10M | $20M | $32M | $51M | $54M |
| Free cash flow margin | -1100.7% | -9337.9% | — | -87.2% | -157.8% | -388.1% | -1101.6% | — | — | -3732.2% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for XENE.
Open XENE in InvestinglyQuestions
What was Xenon Pharmaceuticals's revenue in 2025?
$8M in fiscal 2025, from its 10-K filing.
How much free cash flow does Xenon Pharmaceuticals generate?
-$280M in fiscal 2025 (operating cash flow minus capital spending).
From Xenon Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.